Abstract
Mycophenolate mofetil (MM), an immunosuppressant used after organ transplantation, is also used for treatment of autoimmune myasthenia gravis (MG). A patient with generalized MG was effectively managed with MM but developed CNS lymphoma after 3 years of treatment. Primary CNS lymphoma regressed on withdrawal of MM. Despite minimal short-term side effects and apparent efficacy, chronic treatment of MG with MM may be associated with increased risk of lymphoproliferative disorders.
MeSH terms
-
Aged, 80 and over
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents / therapeutic use
-
Brain Neoplasms / chemically induced*
-
Brain Neoplasms / drug therapy
-
Brain Neoplasms / immunology
-
Cell Transformation, Neoplastic / drug effects
-
Cell Transformation, Neoplastic / immunology
-
Drug Therapy, Combination
-
Female
-
Frontal Lobe / pathology
-
Frontal Lobe / physiopathology
-
Humans
-
Immunity, Cellular / drug effects
-
Immunity, Cellular / immunology
-
Immunosuppressive Agents / adverse effects*
-
Lymphoma, B-Cell / chemically induced*
-
Lymphoma, B-Cell / drug therapy
-
Lymphoma, B-Cell / immunology
-
Magnetic Resonance Imaging
-
Myasthenia Gravis / complications*
-
Myasthenia Gravis / drug therapy*
-
Myasthenia Gravis / immunology
-
Mycophenolic Acid / adverse effects
-
Mycophenolic Acid / analogs & derivatives*
-
Parietal Lobe / pathology
-
Parietal Lobe / physiopathology
-
Prednisone / therapeutic use
-
Pyridostigmine Bromide / therapeutic use
-
Rituximab
-
T-Lymphocytes / drug effects
-
T-Lymphocytes / immunology
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents
-
Immunosuppressive Agents
-
Rituximab
-
Mycophenolic Acid
-
Pyridostigmine Bromide
-
Prednisone